Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: Julie S. Barber-Rotenberg Clear advanced filters

  • In an analysis of long-term safety events in 783 patients treated with T cell therapy in 38 trials, 2.3% of patients developed second primary malignancies, and vector integration analyses revealed no pathological insertions.

    • Julie K. Jadlowsky
    • Elizabeth O. Hexner
    • Joseph A. Fraietta
    Research
    Nature Medicine
    Volume: 31, P: 1134-1144

  • CAR T cells targeting PSMA and engineered to be resistant to immunosuppressive TGFβ signaling exhibit dose-dependent toxicity and expansion following infusion, with some transient antitumor activity, in patients with metastatic castration-resistant prostate cancer

    • Vivek Narayan
    • Julie S. Barber-Rotenberg
    • Naomi B. Haas
    Research
    Nature Medicine
    Volume: 28, P: 724-734

  • Ewing's sarcoma family tumors are dependent on an oncogenic fusion protein, most commonly EWS-FLI1, which interacts with RNA helicase A (RHA) in transcriptional complexes. Erkizan et al. have identified a small molecule that inhibits the interaction of RHA with EWS-FLI1 and impairs the growth of Ewing's sarcoma xenografts in mice. The findings provide evidence that targeting tumor-specific transcription factors may be a feasible approach to treating cancer.

    • Hayriye V Erkizan
    • Yali Kong
    • Jeffrey A Toretsky
    Research
    Nature Medicine
    Volume: 15, P: 750-756